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Wythenshawe Hospital, Wythenshawe, Manchester, UKObjective. To compare current revascularisation practice and outcome in diabetic and non-diabetic patients presenting with
critical limb ischaemia (CLI) to a single vascular surgeon.
Methods. Data for 113 patients presenting with CLI were collected prospectively over a 3-year period. Forty-four (39%)
were diabetic. Treatment was classified as percutaneous angioplasty, arterial reconstruction, primary major amputation, and
conservative therapy. Main outcome measures were 30-day mortality, major amputation, survival, and amputation-free
survival.
Results. Diabetic patients were more likely to present with gangrene, give a history of angina, be treated with nitrates and
statins, and have lower cholesterol levels. No significant differences were found in the initial treatment options between
diabetics and non-diabetics: angioplasty 39 vs 26%, surgical revascularisation 34 vs 33%, primary major amputation 9%
vs 17%, and conservative treatment 11 vs 19% (pZns in all). There were eight deaths (7%) within 30-days. At follow-up
(1–44 months, median 14 months), rates of major amputation and death for the entire population were 23 and 8%,
respectively. The 12-month cumulative survival and amputation-free survival rates were 90 and 72%, respectively. When
comparing diabetic to non-diabetic patients, there were no significant differences in the 30-day mortality (6.8 vs 7.2%, pZ
0.4), cumulative survival (93 vs 89% at 12 months, log-rank test: 0.00, pZ0.9), amputation-free survival (71 vs 73% at 12
months, log-rank test: 0.00, pZ0.99), and major amputation rates (22.7 vs 23.1% at 12 months, pZ0.96). Similarly, there
were no differences in limb salvage rates between diabetic and non-diabetic patients undergoing revascularisation procedures
(78 vs 90% at 12 months, log-rank test: 2.04, pZ0.15).
Conclusions. In current practice, an aggressive multidisciplinary approach in diabetic patients presenting with CLI leads
to similar limb salvage, amputation-free survival, mortality, and major amputation rates to those seen in non-diabetic
patients. The presence of diabetes should not deter clinicians from attempting revascularisation by means of angioplasty or
surgical reconstruction.Keywords: Diabetes; Critical limb ischaemia; Revascularisation; Amputation.Introduction
Critical lower limb ischaemia (CLI) affects one in
2500 people in the UK annually, generating a very
high total national workload.1 The prognosis is poor
and patients have a high risk of major amputation
and death, the 1-year amputation rate being overs an abstract in EUROCHAP 2005, 16th European
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40–70%, respectively.2 One-third of patients with
CLI have diabetes mellitus and they are less likely
to have revascularisation procedures.3 A number of
studies have examined the outcomes of surgical
revascularisation in diabetic patients with CLI,3–12
whereas others have looked at angioplasty outcomes
in this group.13,14 Only few reports have studied the
group of patients with CLI as a whole and
examined the impact of diabetes on clinical outcome
with current practice.15 The purpose of this study
was to compare current revascularisation practice
and clinical outcome in diabetic and non-diabeticEur J Vasc Endovasc Surg 32, 51–59 (2006)
doi:10.1016/j.ejvs.2005.12.019, available online at http://www.sciencedirect.com onved.
S. Awad et al.52patients presenting with CLI to a single vascular
surgeon.Patients and Methods
Over a 36-month period, from January 2001 to
December 2003, a prospective study was undertaken
of consecutive patients presenting with CLI to a single
vascular surgeon (A.N.) based at a major university
hospital. Patient details were entered into a computer
database (Microsoft Excel 2000, Microsoft Limited,
Reading, UK) and comprised information on patient
demographics, risk factors, mode of presentation,
vascular imaging and treatment. Treatment was
classified as percutaneous balloon angioplasty, recon-
structive surgery, primary major amputation, and
conservative therapy. Outcome was recorded with
emphasis on limb salvage, complications and
mortality.
All patients presenting with CLI underwent non-
invasive duplex scanning as first-line investigation,
unless the patient had a scan performed during a
recent previous admission. Angiography was only
requested with a view to revascularisation by angio-
plasty or arterial surgery. During the study period, it
was the policy of our unit to use angioplasty as a first-
line treatment for patients presenting with CLI,
whenever possible. Arterial reconstruction was under-
taken for failed angioplasty or lesions not amenable to
or deemed high risk for percutaneous treatment, a
decision taken jointly by the vascular surgery and
interventional radiology teams.
For the purpose of this study, CLI was defined as
the presence of rest pain, ulceration or gangrene of
greater than 2 weeks duration in the presence of an
arterial lesion identified by duplex or arteriography.
Ankle pressures were not measured routinely as in
common with others the authors found these
thresholds to be of little prognostic value.16,17The
outcome of the patients was based on clinical status
only and not on haemodynamic data. Angioplasty
patients were followed-up clinically and ankle press-
ure and/or duplex imaging were not routinely
performed unless the patient failed to improve or if
further treatment was required. Of patients under-
going arterial reconstruction, only those with vein
bypass grafts underwent periodic duplex scan
surveillance.
Study endpoints were peri-operative mortality and
morbidity, patient survival, amputation-free survival,
and limb salvage. Peri-operative mortality and
morbidity referred to deaths and major complications,
respectively, occurring during the first 30 daysEur J Vasc Endovasc Surg Vol 32, July 2006following angioplasty or surgery. Systemic compli-
cations included respiratory, cardiac, renal, cerebro-
vascular, and gastrointestinal complications. Graft
infection and all others were classified as local
complications. For angioplasty procedures, treatment
success was defined as initial technical success (!30%
residual stenosis) combined with the absence of CLI
recurrence within 30 days of the procedure. Treatment
failure was defined as: (1) initial technical failure, (2)
initial technical success but persistent CLI, or (3) initial
technical success but CLI recurrence within 30 days. A
complication following angioplasty was deemed to be
major if caused death or required emergency surgery
or blood transfusion. Limb salvage was defined as per
the Rutherford classification18 and has only been
applied to therapeutic outcomes and to operations or
other interventions that were intended to avoid an
otherwise inevitable major amputation. Primary
amputation was defined as that amputation without
an attempt at revascularisation. Secondary amputation
was defined as that performed following an attempt at
revascularisation (angioplasty or surgical reconstruc-
tion). Major amputation was defined as per Ruther-
ford classification as loss of a sufficiently functional
foot remnant (to allow standing and walking) and
necessitating the fitting of a prosthesis, i.e. above and
below knee amputations for the purposes of this
study.18 Minor amputation constituted ray and fore-
foot amputations.
Statistical analysis was performed using the SPSS
(version 12.0) statistical software (SPSS, Chicago, IL,
USA). Chi-square test or Fischer’s exact test, as
appropriate, was used to compare categorical data
and the unpaired t-test for continuous data. Non-
parametric Mann–Whitney U-test was used to
compare length of hospital stay. Patient survival,
amputation-free survival and limb salvage were
calculated by the Kaplan–Meier method using the
log-rank test. A Cox (semi-parametric) regression
model was employed to determine the combination
of potential factors (i.e. cardiac, respiratory, diabetes)
that affect the form of the hazard function. A stepwise
selection process was used to identify the statistically
significant factors. A p value!0.05 was considered to
be statistically significant.Results
There were 113 patients (113 limbs) presenting with
CLI of whom 62 (55%) were male. The meanGSD age
was 69G14 years. There were 44 (39%) diabetic
patients of whom three (7%) were type I. Of those
with type-II diabetes, five (11%) were diet-controlled,
Table 1. Patient demographics and mode of presentation
Diabetic (nZ44) (39%) Non-diabetic (nZ69) (61%) p Value
Male/female 29 (66%)–15 (34%) 33 (48%)–36 (52%) 0.1
Age (years), meanGSD (range) 68.2G12.4 (36–95) 69.9G14.9 (33–95) 0.5
Mode of presentation
Rest pain 32 (73%) 57 (83%) 0.2
Ulceration 24 (55%) 26 (38%) 0.1
Gangrene 20 (45%) 18 (26%) 0.03
Non-salvageable limb 3 (7%) 9 (13%) 0.2
Diabetes and CLI 5316 (36%) were on oral hypoglycaemics, and 24 (55%)
were on insulin. Patient demographic data, mode of
presentation, cardiovascular risk factors, history of
previous angioplasty, vascular reconstruction and
amputation, and medication are summarised in
Tables 1 and 2, respectively. There were no differences
between the two groups other than that diabetics
were more likely to present with gangrene (20/44 vs
18/69, pZ0.03), give a history of angina (25/44 vs
20/69, pZ0.01), be treated with antianginals (22/44
vs 19/69, pZ0.03) and statins (18/44 vs 15/69,
pZ0.03) and have lower cholesterol levels (3.88G
1.28 vs 4.78G1.2 mmol/L, pZ0.01). No differences
were found between the two groups in having
undergone a previous intervention (angioplasty or
surgery) on either the symptomatic or the contral-
ateral limb, or a major amputation of the contralateral
limb (Table 2).Table 2. Patient risk factors, history of previous angioplasty or vascula
drug history
Diabetic (nZ44)
Risk factors
Smoking history 33 (75%)
Hypertension 25 (58%)
Angina 25 (58%)
Cardiac failure 11 (26%)
Cerebrovascular disease 12 (28%)
Renal impairment* 13 (30%)
Respiratory disease 10 (23%)
Previous angioplasty/surgery
Symptomatic limb 7 (16%)
Contralateral limb 6 (14%)
Contralateral amputation
Major 6 (14%)
Minor 2 (5%)
Medications
Aspirin 20 (45%)
Clopidogrel 6 (14%)
Warfarin 5 (11%)
Antihypertensives 21 (48%)
Statins 18 (41%)
Antianginals 22 (50%)
Diuretics 19 (43%)
Cholesterol level (mmol/L)
MeanGSD (range) 3.88G1.28 (1.5–7)
Creatinine (mmol/L)
MeanGSD (range) 118G49 (46–250)
Patients with raised creatinine* 13
* Renal impairment and raised creatinine were defined as creatinineAll patients underwent duplex scanning first,
followed by arteriography in 88 (78%) of cases. Details
of the angiographic findings appear in Table 3. There
were no significant differences in the number of
angiograms performed in the two groups (diabetic vs
non-diabetic, 86 vs 72%, pZ0.1). Although we expected
diabetic patients to have distal vessel disease more
frequently, this difference did not achieve statistical
significance (82 vs 72%, pZ0.3). The management
options employed in the 113 patients are summarised
in Fig. 1. Revascularisation was attempted in 79 patients
(70%). The remaining 34 patients proceeded to primary
amputation or were managed conservatively.
Overall 16 patients (14%), four of whom were
diabetics, underwent primary major amputation. In
the diabetic group, two patients presented with a non-
salvageable limb and underwent above-knee amputa-
tion, whereas the other two had extensive medicalr reconstruction, previous amputation in the contralateral limb and
Non-diabetic (nZ69) p Value
47 (71%) 0.4
35 (51%) 0.5
20 (29%) 0.01
9 (13%) 0.1
15 (22%) 0.5
11(16%) 0.1
17 (25%) 0.8
10 (15%) 0.8
6 (9%) 0.3
5 (7%) 0.2
0 (0%) 0.1
24 (35%) 0.3
7 (10%) 0.6
3 (4%) 0.2
37 (54%) 0.5
15 (22%) 0.05
19 (28%) 0.03
19 (28%) 0.09
4.78G1.2 (2.0–8.3) 0.01
99G31 (55–185) 0.02
11 0.1
levelO130 mmol/L.
Eur J Vasc Endovasc Surg Vol 32, July 2006
Table 3. Angiography findings
Diabetic (nZ44) Non-diabetic (nZ69) p Value
Number of angiograms 38 (86%) 50 (72%) 0.1
Level of disease
Suprainguinal disease 11 (29%) 24 (48%) 0.1
Infrainguinal disease 34 (90%) 42 (84%) 0.5
Infrapopliteal disease 31 (82%) 36 (72%) 0.3
S. Awad et al.54co-morbidities of cardiac and renal failure and deemed
medically unfit to undergo revascularisation. Both had
a below-knee amputation. In the non-diabetic group
(12 patients), the reasons for primary amputation were
as follows: nine patients presented with a non-
salvageable limb, two had disease not amenable to
revascularisation, and one patient was considered
medically unfit for intervention. The likelihood to
undergo primary amputation was no different in
diabetics when compared to non-diabetics (4/44 vs
12/69, pZ0.2).
A further 18 patients with CLI, five of which were
diabetic, were treated conservatively. Reasons for
conservative management in diabetics were: three
were medically unfit and too frail for intervention, one
declined treatment, and one had disease not amenable
to revascularisation; in the non-diabetic group (nZ13),
four had been admitted with acute-on-chronic ischae-
mia and symptoms improved after infusion of
intravenous heparin, three had disease amenable
only to surgical reconstruction but did not feel
symptoms were severe enough to warrant surgery,
five patients had severe disease not amenable to
revascularisation, and one’s symptoms improvedSurgery
38 pts (34%) 
15 D, 23 nD 
Angioplasty
41 pts (36%) 
20 D, 21 nD 
Additional 
surgical 
reconstruction
6 pts  
3 D, 3 nD
Failed 
angioplasty
4 pts (all D):
1 fem-distal 
2 BKA 
1 AKA 
113 patients with 
44 D, 69 nD 
Fig. 1. Treatment in the 113 limbs with CLI. Pts, patients; CLI,
axillo-bifemoral bypass graft.
Eur J Vasc Endovasc Surg Vol 32, July 2006after medical optimisation. The likelihood of having
conservative management was statistically no differ-
ent between the two groups (5/44 vs 13/69, pZ0.3).
Details of the revascularisation procedures, both
angioplasty and arterial reconstruction, are presented
in Table 4. Diabetics and non-diabetics were equally
likely to be offered revascularisation (35/44 vs 44/69,
pZ0.1).
A total of 35 patients (31%), 17 diabetic and 18 non-
diabetic, underwent angioplasty as a first-line treat-
ment. There were a total of 39 angioplasty sites in 35
limbs: iliac in 13, superficial femoral/popliteal in 19,
profunda femoris in one, and tibioperoneal trunk and
calf vessels in six cases. None of the limbs in this
patient population underwent stenting. Both diabetic
and non-diabetic patients were equally likely to be
offered angioplasty as a first-line revascularisation
option (17/44 vs 18/69, pZ0.2). Furthermore, of those
patients that proceeded to revascularisation, similar
numbers underwent angioplasty amongst diabetic
and non-diabetic patients (17/35 vs 18/44, pZ0.5).
Angioplasty as a preliminary step to arterial recon-
struction was performed in six additional cases. Two
diabetic patients underwent femoro-femoral crossoverConservative
treatment
18 pts (16%) 
5 D, 13 nD
CLI  
Primary major 
amputation
16 pts (14%) 
4 D, 12nD 
critical limb ischaemia; D, diabetic; nD, non-diabetic; AxBF,
Table 4. Details of angioplasty and arterial bypass procedures
Diabetic (nZ44) Non-diabetic (nZ69) p Value
Revascularisation procedures (nZ79) 35 (80%) 44 (64%) 0.1
Angioplasty (nZ35) 17 18
% of total patients 39% 26% 0.2
% of those revascularised 49% 41% 0.5
Angioplasty site:
Iliac 3 10
SFA/popliteal 8 11
Profunda femoris 1 0
TPT/calf vessels 5 1
Arterial reconstructionsGangio-
plasty (nZ45)
19 (43%) 26 (38%) 0.6
Surgical intervention alone (nZ38) 15 (34%) 23(33%) 0.9
Operative details
Extra-anatomic bypass 3 7
Common femoral endarterectomy 1 3
Femoro-popliteal bypass 6 10
Femoro-distal bypass 7 5
Popliteal-distal bypass 1 1
Conduit material
Autogenous vein 8 (42%) 11 (42%) 1
Synthetic graft 7 (37%) 12 (46%) 0.5
Composite 2 0
SFA, superficial femoral artery; TPT, tibioperoneal trunk; extra-anatomic bypass includes, aorto-bifemoral axillo-bifemoral, ilio-iliac and
femoro-femoral crossover bypass graft.
Diabetes and CLI 55and femoro-popliteal bypass grafting, respectively,
whereas in the non-diabetic group, there were two
common femoral endarterectomies, one femoro-popli-
teal and one popliteal-distal bypass.
There were four treatment failures following angio-
plasty, all in the diabetic group; one underwent femoro-
distal bypass, two had a below-knee amputation due to
non-reconstructable run-off disease, and one had an
above-knee amputation due to extensive medical
co-morbidities. The latter eventually died on the third
post-operative day due to myocardial infarction. There
were no angioplasty failures in the non-diabetic group.
Therefore, treatment success was achieved in 31 (89%) of
the 35 patients who had angioplasty as a first-line
treatment. Angioplasty was less likely to be successful
in diabetics (13/17 vs 18/18, pZ0.04).
Finally, a total of 45 patients underwent arterial
reconstruction; 38 had surgery alone, six had com-
bined angioplasty and surgery, whereas one was
operated upon after a failed angioplasty. Details of
the surgical procedures performed in the two groups
appear in Table 4. The likelihood to undergo arterial
reconstruction was no different in diabetics when
compared to non-diabetics, either when considering
the total population (15/44 vs 23/69, pZ0.9) or only
those who proceeded to revascularisation (19/35 vs
26/44, pZ0.6). There were no differences in the choice
of bypass graft material between the two groups.
Five patients in the surgery group, three of whom
were non-diabetic, died during the first 30 days
(30-day operative mortality of 11%). Four patients(two diabetic) died following an axillo-femoral bypass,
two from cardiac causes, one from pneumonia and the
last from multi-organ dysfunction syndrome. Finally,
one non-diabetic died following a femoro-popliteal
bypass due to cardiac causes. Diabetics had no higher
30-day operative mortality rate than non-diabetics
(1/19 vs 4/26, pZ0.3).
A total of 27 complications, both systemic and local,
were encountered in 20 patients in the surgery group
during the first 30 days (20/45, 44%). Eight of these
patients were diabetic. There were 13 systemic and 14
local complications. Systemic included eight cardiac,
two respiratory and three renal complications. Local
complications were 13 wound infections and one graft
infection. There were no differences in the 30-day
overall, systemic, and local complication rates
between diabetic and non-diabetic patients (8/19 vs
12/26, pZ0.79, patients with all complications; 4/19 vs
9/26, pZ0.26, systemic; and 7/19 vs 7/26, pZ0.48,
local, respectively). There was only one graft occlusion
in a non-diabetic patient who had undergone femoro-
distal bypass.Thirty-day outcome
Details of the mortality and morbidity within the first
30 days for the entire group are summarised in Table 5.
Diabetic and non-diabetic patients had similar length
of hospital stay, i.e. median 19 days (range 1–87) vs
13 days (range 1–111), pZ0.2. The 30-day mortality of
all patients presenting with CLI during the studyEur J Vasc Endovasc Surg Vol 32, July 2006
Table 5. Mortality and morbidity within the first 30 days in the 113
patients irrespective of the method of treatment
30-day outcome Diabetic
(nZ44)
Non-diabetic
(nZ69)
p Value
30-day mortality 3 5 0.6
Causes of death
Cardiac 3 2
Respiratory 0 1
Sepsis 0 1
MODS 0 1
Complications (any)* 22 31
Pts with complications (any) 14 (32%) 20 (29%) 0.7
Systemic complications* 12 20
Cardiac 6 10
Respiratory 4 7
Gastrointestinal 1 1
Renal 1 2
Local complications* 10 11
Wound infection 10 9
Graft infection 0 2
MODS, multiple organ dysfunction syndrome.
* Patients may have developed more than one complication.
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126010809007205403601800-180
Cu
m
ul
at
ive
 s
ur
viv
al
1.00
.90
.80
.70
.60
Group
Non-diabetic
Non-diabetic
-censored
Diabetic
Diabetic-censored
All patients
All patients
-censored
Numbers at risk 
Days 0 365 730 1095
Total 113 45 14 1 
DM 44 14 6 0 
Non-DM 69 31 8 1 
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S. Awad et al.56period, irrespective of method of treatment, was 7%
(eight deaths). This was no different amongst the two
groups (4/44 vs 4/69, pZ0.4). On multivariable
analysis, neither diabetes nor any other risk factors
were found to be statistically significant predictors of
30-day mortality. Complications were encountered in
34 patients (30%), again no different in diabetics when
compared to non-diabetic patients (14/44 vs 20/69,
pZ0.7). Limb salvage was achieved in 70 out of the 79
patients undergoing revascularisation (89%), again
with no difference between the two groups (diabetic vs
non-diabetic, 30/35 vs 40/44, pZ0.5).Follow-up (days)
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Fig. 3. Cumulative amputation-free survival (Kaplan–Meier
curves) for the entire patient sample (113 patients). No
difference was seen between diabetic and non-diabetic
patients (log-rank test: 0.00, pZ0.99).Follow-up
The median follow-up was 14 months (range 1–44); 15
months (range 2–44) for diabetic and 13 months (range
1–37) for non-diabetic patients (pZ0.15). Eleven
patients were lost to follow-up, five and six patients
in the diabetic and non-diabetic groups, respectively.
There was one further death during follow-up. This
was an elderly, non-diabetic patient who died 12
months later from cardiac causes. Therefore, the
12-month survival for the entire population was 92%.
Patient cumulative survival is presented graphically in
Fig. 2 by means of Kaplan–Meier curves. The
12-month cumulative survival was 93% in diabetic
and 89% in non-diabetic patients (log-rank test: 0.00,
pZ0.9). Amputation-free survival for the entire patient
sample is also presented graphically in Fig. 3. The
12-month cumulative amputation-free survival rates
were 71 and 73%, respectively. Similarly, no differences
were seen between the two groups (log-rank test: 0.00,
pZ0.99). Finally, amongst the 79 patients whoEur J Vasc Endovasc Surg Vol 32, July 2006
Diabetes and CLI 57underwent revascularisation procedures, there was no
difference between the two groups, the 12-month
cumulative limb salvage rates for the entire group,
diabetic, and non-diabetic patients being 85, 78, and
90%, respectively (Fig. 4, log-rank test: 2.04, pZ0.15).
The overall limb salvage rates following angioplasty
and arterial reconstruction at the end of follow-up was
89 and 87%, respectively, no different amongst diabetic
and non-diabetic patients (angioplasty 13/17 vs 18/18,
pZ0.07, surgery 17/19 vs 22/26, pZ0.5). When Cox
regression analysis was performed, diabetes was not
found to be a statistically significant predictor of
survival, amputation free-survival, or limb salvage.
The only significant variables for survival was the
presence of cardiac (hazard ratio 8.991 [95% CI: 1.115–
72.498; pZ0.039]) and respiratory disease (hazard ratio
5.765 [95% CI; 1.429–23.255; pZ0.014]).
To completion of the study, major amputation (both
primary and secondary) and death rates were 23 and
8%, respectively. The overall major amputation rates
were similar amongst diabetics and non-diabetics
(10/44 vs 16/69, pZ0.96).Follow-up (days)
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Fig. 4. Cumulative limb salvage (Kaplan–Meier curves) in
diabetic and non-diabetic patients that underwent revascu-
larisation. No difference was seen between diabetic and non-
diabetic patients (log-rank test: 2.04, pZ0.15).Discussion
Diabetic patients comprise a significant proportion of
those presenting with CLI. Previous studies have
shown the clinical results following arterial recon-
struction to be worse in diabetics with an increased
mortality4–8 and inferior limb salvage rates.3,7,9 Simi-
larly, it has been shown that presence of diabetes
correlates with worse clinical outcomes following
percutaneous angioplasty.13 As a result, some remain
sceptical about whether diabetics really profit from
revascularisation.6 A number of recent series, how-
ever, have challenged these results demonstrating that,
with an aggressive approach, diabetic patients can
achieve similar outcomes to non-diabetics.6,10–12,14,19
One area that is infrequently addressed in reports
dealing with CLI is the outcome of the entire
population presenting to the vascular surgeon and
not only of those being offered revascularisation. The
majority of the reports focus on the outcome of
patients undergoing either revascularisation as a
whole, or specific surgical and endovascular pro-
cedures, such as femoro-distal bypass or balloon
angioplasty. A national survey in the UK found that
60% of patients were suitable for revascularisation
while a further 20% needed a primary amputation.1 In
our study, revascularisation was attempted in 70% of
all patients (80% in diabetic and 64% in non-diabetic
patients) while 14% needed a primary amputation.
These figures are comparable, if not somewhat better
than those reported by others who looked at outcomes
of CLI. The percentages of revascularisation and
primary amputations in the reported series ranged
from 48 to 74%, and 8 to 35%, respectively.1,3,15,20–24
Finally, there are a number of patients with CLI that
are being treated conservatively. Some may be too
unwell or too frail to undergo further investigation
and treatment, and, therefore, conservative manage-
ment and palliation is the only option.15 Others may
decline further intervention or may be wheel chair or
bed bound with no prospect of mobilisation. Eighteen
patients (16%) were treated conservatively in our
series. This contrasts with the 52% of patients being
treated conservatively in a contemporary series from a
British District General Hospital.15 Overall, diabetic
and non-diabetic patients were equally likely to be
offered revascularisation by means of surgery or
angioplasty, primary amputation, or conservative
treatment in our series.
Percutaneous balloon angioplasty has been central
to improving outcomes in CLI and in many insti-
tutions has increasingly become the first-line
treatment for such patients.14,19,24–29 Some of
the advantages of angioplasty are that it isEur J Vasc Endovasc Surg Vol 32, July 2006
S. Awad et al.58minimally-invasive, it is performed under local
anaesthesia, and it is well-tolerated. Furthermore, it
is ideally suited to elderly and frail patients deemed at
high risk for arterial reconstructive surgery. The latter
may be associated with significant morbidity and
carries the risks of graft occlusion and soft tissue or
graft infection, including MRSA, a particular problem
in diabetics with tissue loss. In this context, angio-
plasty is preferred to bypass surgery as the peri-
procedure morbidity and mortality rates, even in this
group, are low. Finally, angioplasty and surgery are
not mutually exclusive, and, in most cases, the former
does not preclude the latter.25 Of course, conventional
transluminal angioplasty has limitations as it is not
suitable for long stenoses or occlusions, a problem,
however, now overcome with the advent of subintimal
angioplasty.26–30 Hynes et al. have recently reported
the number of attempted revascularisations to have
doubled since the introduction of the subintimal
angioplasty.23 In our patients, the subintimal tech-
nique was routinely employed in all femoropopliteal
occlusions, whereas stenoses were usually treated
intraluminally. Others have adopted a much more
aggressive policy using the subintimal recanalisation
as a first-line option in the majority of cases.14,23–30 A
total of 35 patients (31%) underwent angioplasty in
this series. This comprised 44% of those amenable to
revascularisation, as opposed to 16–69% quoted by
others.15,19,20,23–30
The overall limb salvage rate following angioplasty
at the end of follow-up in our study was 89%. There
were no differences detected between the diabetic and
non-diabetic groups. This is in accordance with
previous studies which have demonstrated similar
limb salvage rates with angioplasty between diabetic
and non-diabetic patients.8,14,19 Close liaison between
surgeon and interventional radiologist regarding case
selection and suitability for angioplasty has ensured a
high technical success rate of 89%, a figure similar to
the 78–89% reported by others.14,27,30 It is of note that
all the technical failures in this series occurred in the
diabetic group, a finding which has been demon-
strated by others.14,30
In the present series, 56% of patients amenable to
revascularisation had reconstructive surgery, a figure
similar to those reported in two recent prospective
studies examining outcomes in CLI in the UK.15,20 A
similar proportion of diabetic and non-diabetic
patients underwent surgical reconstruction (51 vs
59%) and the limb salvage rate at end of follow-up
overall, in diabetics, and non-diabetics was 87, 89.5
and 85%, respectively. The high success rate of surgical
revascularisations in diabetics is encouraging and,
again, emphasises in common with other studies6,10,12Eur J Vasc Endovasc Surg Vol 32, July 2006that there is a role for surgery in these patients despite
the perceived poorer outcome.4–9
A limitation of our study is the small numbers.
Although both univariate and multivariable analysis
suggest that diabetes has no effect on any of the
outcomes examined, it may be that statistically
significant differences could not be detected because
of the small sample size.
In conclusion, diabetes seems to have no significant
impact on the current revascularisation practice in
patients with CLI, as it influences neither the type of
treatment being offered, nor the clinical outcome of
these patients. Given a similar limb salvage rate in
those undergoing revascularisation procedures, dia-
betics should not be prejudiced against and the
decision to amputate or treat conservatively rather
than revascularise should be based on suitability for
revascularisation, appropriate anatomy, and the
presence of medical conditions other than diabetes. It
is clear that the modern management of CLI has
evolved. The increase in technical expertise and the
advent of balloon angioplasty, and in particular the
subintimal technique, have revolutionised the treat-
ment of CLI in patients who previously would have
been deemed too high risk to undergo surgical
revascularisation. The modern management of co-
morbidities, such as hypertension, coronary artery
disease, diabetes, and hypercholesterolaemia, is also
likely to have contributed to the improved outcomes in
diabetics presenting with CLI. This prospective study
has shown that by advocating an aggressive approach
to revascularisation, equally good results, in terms of
survival and limb salvage, can be achieved in both
diabetic and non-diabetic patients, despite the
presence of increased medical co-morbidity in the
former. Careful pre-operative optimisation of risk
factors, close liaison between vascular surgeon and
interventional radiologist, liberal use of revascularisa-
tion procedures and offering angioplasty as a first-line
treatment in selected patients, are all equally import-
ant factors that need to be addressed if a favourable
outcome is to be achieved.References
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